Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2020 Aug 7:ciaa1097. doi: 10.1093/cid/ciaa1097

COVID-19 in solid organ transplant: A multi-center cohort study

Olivia S Kates 1, Brandy M Haydel 2, Sander S Florman 2, Meenakshi M Rana 3, Zohra S Chaudhry 4, Mayur S Ramesh 4, Kassem Safa 5, Camille Nelson Kotton 6, Emily A Blumberg 7, Behdad D Besharatian 7, Sajal D Tanna 8, Michael G Ison 8,9, Maricar Malinis 10, Marwan M Azar 10, Robert M Rakita 1, Jose A Morillas 11, Aneela Majeed 11, Afrah S Sait 12, Mario Spaggiari 13, Vagish Hemmige 14, Sapna A Mehta 15, Henry Neumann 15, Abbasali Badami 16, Jason D Goldman 1,17, Anuradha Lala 18, Marion Hemmersbach-Miller 19, Margaret E McCort 14, Valida Bajrovic 20, Carlos Ortiz-Bautista 21, Rachel Friedman-Moraco 22, Sameep Sehgal 23, Erika D Lease 24, Cynthia E Fisher 1,#, Ajit P Limaye 1,#,; UW COVID-19 SOT Study Team
PMCID: PMC7454362  PMID: 32766815

Abstract

Background

The COVID-19 pandemic has led to significant reductions in transplantation, motivated in part by concerns of disproportionately more severe disease among solid organ transplant (SOT) recipients. However, clinical features, outcomes, and predictors of mortality in SOT recipients are not well-described.

Methods

We performed a multi-center cohort study of SOT recipients with laboratory-confirmed COVID-19. Data were collected using standardized intake and 28-day follow-up electronic case report forms. Multivariable logistic regression was used to identify risk factors for the primary endpoint, 28-day mortality, among hospitalized patients.

Results

Four hundred eighty-two SOT recipients from >50 transplant centers were included: 318 (66%) kidney or kidney/pancreas, 73 (15.1%) liver, 57 (11.8%) heart, and 30 (6.2%) lung. Median age was 58 (IQR 46-57), median time post-transplant was 5 years (IQR 2-10), 61% were male, and 92% had ≥1 underlying comorbidity. Among those hospitalized (376 [78%]), 117 (31%) required mechanical ventilation, and 77 (20.5%) died by 28 days after diagnosis. Specific underlying comorbidities (age >65 [aOR 3.0, 95%CI 1.7-5.5, p<0.001], congestive heart failure [aOR 3.2, 95%CI 1.4-7.0, p=0.004], chronic lung disease [aOR 2.5, 95%CI 1.2-5.2, p=0.018], obesity [aOR 1.9, 95% CI 1.0-3.4, p=0.039]) and presenting findings (lymphopenia [aOR 1.9, 95%CI 1.1-3.5, p=0.033], abnormal chest imaging [aOR 2.9, 95%CI 1.1-7.5, p=0.027]) were independently associated with mortality. Multiple measures of immunosuppression intensity were not associated with mortality.

Conclusions

Mortality among SOT recipients hospitalized for COVID-19 was 20.5%. Age and underlying comorbidities rather than immunosuppression intensity-related measures were major drivers of mortality.

Keywords: COVID-19, SARS-CoV-2, coronavirus, transplantation, solid organ transplantation


Articles from Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America are provided here courtesy of Oxford University Press

RESOURCES